Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Thermo Fisher Scientific is a leading research and development company and provider of laboratory products and services headquartered in Waltham. On August 23, Reuters announced that Novo Nordisk has entered into a partnership agreement with Thermo Fisher Scientific, under which it will be responsible for filling the Wegovy injection pens. Moreover, Thermo Fisher Scientific's Non-GAAP P/E [TTM] is 24.35x, which is 32.17% higher than the sector average and 1.1% lower than the average over the past five years.

Thermo Fisher Scientific: Transforming Healthcare Leadership Post-COVID-19 Pandemic

Thermo Fisher Scientific provides laboratory instruments, reagents, and consumables for scientific research and healthcare applications. These are the 'picks and shovels' for healthcare and life sciences sectors. Thermo Fisher generates recurring revenue through the adoption of single-use systems in the pharmaceutical industry, increasing. The current valuation offers me an annualized return of between 8% and 9% over the next 5 years, so I decided to assign a 'hold' rating.

Thermo Fisher: I'm Waiting For A Better Valuation In This High-Quality Business

Thermo Fisher Scientific stands strong in the healthcare sector, prioritizing growth, innovation, and sustainability, justifying its valuation despite recent market challenges. TMO showcases resilience, leveraging long-term healthcare market trends, hinting at consistent annual growth potential despite the current stock price decline. TMO's strategic strengths, including market localization in China and M&A proficiency, along with favorable valuation projections and a robust balance sheet, set the stage for continued outperformance.

Thermo Fisher: An Up To 35% Undervalued Healthcare Gem I Like On Weakness

Thermo Fisher Scientific Inc. (NYSE:TMO ) Morgan Stanley 21st Annual Global Healthcare Conference September 13, 2023 8:50 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning.

Thermo Fisher Scientific Inc. (TMO) Morgan Stanley 21st Annual Global Healthcare Conference - (Transcript)

STOCKHOLM , Sept. 13, 2023 /PRNewswire/ -- Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services.

Devyser and Thermo Fisher Scientific collaborate to promote laboratory services to advance pharmaceutical research

This underperformance of TMO stock can partly be attributed to declining sales of its Life Sciences segment due to lower COVID-19-related demand.

Will Thermo Fisher Scientific Stock Recover To Its Pre-Inflation Shock Highs?

Mettler-Toledo

TMO stock has lacked the ability to outperform the S&P 500 since January.

Two Medical Stocks Exit Long-Term Leaders; Kinsale, SPS Commerce Thrive

Thermo Fisher's clinical research division will aid in increasing community health clinics' capacity to participate in clinical studies.

Thermo Fisher (TMO) to Advance Clinical Research With New Pact

Thermo Fisher (TMO) launches the next-generation Gibco CTS Detachable Dynabeads platform.

Thermo Fisher (TMO) Adds New Platform to CTS Product Portfolio

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, has been recognized by the R&D 100 Awards, honoring the top 100 revolutionary products in science and technology from around the world, for three unique innovations that aid researchers' and scientists' work in a variety of life science applications, including bioproduction and small-molecule analysis. The three award-winning Thermo Fisher innovations include: The Thermo Scientific™ DynaSpin.

Thermo Fisher Scientific Recognized by R&D 100 Awards for Innovations in Science and Technology

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the National Minority Quality Forum (NMQF), an independent not-for-profit research and education organization, today announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF's Alliance for Representative Clinical Trials (ARC). The collaboration supports biopharmaceutical and biotech customers in meeting regulatory expe.

Thermo Fisher Scientific and National Minority Quality Forum Collaborate to Make Clinical Research More Accessible to Historically Underserved Communities

Oracle

Roku

AeroVironment

Salesforce

CrowdStrike

First Solar

GitLab

Southwest Airlines

Microsoft

ServiceNow

Block

Toast

Zscaler

Here are some of the tickers on my radar for Wednesday, Sept. 6, taken directly from my reporter's notebook.

Here are the 14 stocks Jim Cramer is watching, including Oracle, Roku and Southwest

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Gibco CTS Detachable Dynabeads (CTS Detachable Dynabeads)*, its next-generation platform of Dynabeads with the first active release mechanism of its kind for clinical trial and commercial manufacturing use. The active release mechanism of CTS Detachable Dynabeads utilizes a release buffer that helps enable users to actively detach Dynabeads from a target cell at any point dur.

Thermo Fisher Scientific Helps Accelerate Cell Therapy Manufacturing with a Next-Generation Platform of Gibco™ CTS™ Detachable Dynabeads™

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 8:50 a.m. (EDT). You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc.

Thermo Fisher Scientific to Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023

Azenta

Waters

Here's a look at 3 leading robo-lab company stocks. When you think of dexterous professions, you often think of doctors or musicians.

Robo-Lab Stocks: 3 Robotics Companies Changing the Research Game

GlaxoSmithKline

JPMorgan Chase & Co

Medtronic

NVIDIA

Walmart

Emulating the moves of hedge fund stock pickers, and some of the most successful hedge funds can produce sizable profits for retail investors. In fact, here are seven of the top institutional stock picks you may want to consider as we near the last few months of 2023.

7 Stocks Hedge Funds Are Loading Up On

Applied Materials

Dollar General

Danaher

Dolby Laboratories

Equinix

Gilead Sciences

Garmin

Martin Marietta Materials

Monolithic Power Systems

M&T Bank

Norfolk Southern

Old Dominion Freight Line

SAP SE

Sony

Constellation Brands

Toronto-Dominion Bank

TC Energy

Verisk Analytics

This article presents the highest-quality Dividend Challengers, companies listed on U.S. exchanges with consistently higher annual dividend payouts for 5-9 years. The top 20 highest-quality Dividend Challengers are identified based on a quality scoring system, with Toronto-Dominion Bank, Dolby Laboratories, and Thermo Fisher Scientific making the top three. The article also highlights stocks trading at favorable valuations and offering compelling metrics for income-focused, growth-oriented, value-driven, and total-return investors.

The Highest Quality Dividend Challenger Summary

Thermo Fisher Scientific Inc. (NYSE:TMO ) Handelsbanken 3rd Annual Life Science Innovation Day August 30, 2023 10:00 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Mattias Häggblom - Handelsbanken Mattias Häggblom So good morning for those of you joining us in the U.S., and good afternoon for those over in Europe. A warm welcome.

Thermo Fisher Scientific Inc. (TMO) Handelsbanken 3rd Annual Life Science Innovation Day (Transcript)

Thermo Fisher excels in diversified life sciences sectors, bolstered by innovative R&D, efficient PPI systems, and economies of scale. Thermo Fisher aims for 7%-9% organic growth, outpacing its 4%-6% growing end markets, through strategic acquisitions, innovation, and diversified revenue streams. Thermo Fisher balances capital between high-ROI reinvestment and shareholder returns, excelling in strategic acquisitions that drive synergistic growth and value.

Thermo Fisher Scientific: A High-Quality Investment For Double-Digit Returns

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

Why Is Thermo Fisher (TMO) Down 3.9% Since Last Earnings Report?

Thermo Fisher (TMO) announces the commercial launch of the EXTENT Solution with IVDR certification.

Thermo Fisher's (TMO) EXTENT Solution Makes Commercial Launch

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Handelsbanken 3rd Annual Life Science Innovation Day on Wednesday, August 30th, 2023 at 10:00 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the w.

Thermo Fisher Scientific to Present at Handelsbanken 3rd Annual Life Science Innovation Day on August 30th, 2023

Emerson Electric

Intuitive Surgical

The world is becoming increasingly automated paving the way for robotics stocks moving forward. Sector growth is expected to reach double digits on an annualized basis and ranges from the low to mid-teens depending on the source In either case, capital invested in the sector has a reasonable chance of increasing in value.

3 Millionaire-Maker Robotics Stocks to Hold Through Thick and Thin

BIRMINGHAM, England--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the commercial launch of the EXENT® Solution, after receiving IVDR certification*. The EXENT solution is a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma which, according to the World Health Organization in 2020, is the second most prevalent blood cancer w.

Thermo Fisher Scientific Announces the Launch of the EXENT® Solution with IVDR Certification

Thermo Fisher's (TMO) CytoScan HD Accel array can save labs weeks or even months by accelerating the time it takes to get findings from cytogenetic research.

News for Thermo Fisher Scientific Stock (TMO)